| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T129 |
0-203 |
Sentence |
denotes |
If IgA/M and IgG were both available, the combined IgM/A and IgG sensitivity result was consistently higher than the separate interpretation (range 14–71% on day 2–7 and 88–94% on day 8–18; see Table 2). |
| T130 |
204-212 |
Sentence |
denotes |
Table 2. |
| T131 |
213-259 |
Sentence |
denotes |
Sensitivity and specificity of all test assays |
| T132 |
260-353 |
Sentence |
denotes |
Test Assay Sensitivity day 2–7 Sensitivity day 8–18 Overall sensitivity day 2-d18 Specificity |
| T133 |
354-424 |
Sentence |
denotes |
IgM* IgG IgM* + IgG IgM* IgG IgM* + IgG IgM* IgG IgM* + IgG IgM* IgG |
| T134 |
425-465 |
Sentence |
denotes |
Point-of-care test |
| T135 |
466-580 |
Sentence |
denotes |
Corona Virus (COVID-19) Combined IgM/IgG Rapid test (Sol scientifics) 57% 14% 57% 94% 88% 94% 83% 65% 83% 79% 100% |
| T136 |
581-677 |
Sentence |
denotes |
COVID-19 IgG/IgM Rapid test Cassette (Orient Gene) 43% 29% 43% 94% 88% 94% 78% 70% 78% 100% 100% |
| T137 |
678-721 |
Sentence |
denotes |
SARS-CoV-2 Ab rapid test (Wantai) n.a. n.a. |
| T138 |
722-735 |
Sentence |
denotes |
43% n.a. n.a. |
| T139 |
736-749 |
Sentence |
denotes |
94% n.a. n.a. |
| T140 |
750-758 |
Sentence |
denotes |
78% n.a. |
| T141 |
759-763 |
Sentence |
denotes |
100% |
| T142 |
764-856 |
Sentence |
denotes |
COVID-19 IgG/IgM RAPID TEST (PRIMA PROFESSIONAL) 0% 29% 29% 50% 81% 88% 35% 65% 70% 95% 100% |
| T143 |
857-965 |
Sentence |
denotes |
Diagnostic Kit for IgG/IgM Antibody to SARS-CoV-2 (WIZ BIOTECH) 14% 14% 14% 94% 94% 94% 70% 70% 70% 95% 100% |
| T144 |
966-1029 |
Sentence |
denotes |
Enzyme-Linked Immunosorbent Assay (ELISA) |
| T145 |
1030-1103 |
Sentence |
denotes |
Anti-SARS-CoV-2 (EUROIMMUN)* 57% 29% 57% 94% 88% 94% 83% 70% 83% 95% 100% |
| T146 |
1104-1196 |
Sentence |
denotes |
Novel Coronavirus COVID-19 (Epitope Diagnostics) 29% 71% 71% 69% 94% 94% 57% 87% 87% 95% 89% |
| T147 |
1197-1290 |
Sentence |
denotes |
SARS-CoV-2 IgG ELISA Kit (Creative Diagnostics) 29% 14% 29% 94% 88% 94% 74% 65% 74% 100% 100% |
| T148 |
1291-1344 |
Sentence |
denotes |
Human Anti-2019 nCoV(N) IgG ELISA kit (Finetest) n.a. |
| T149 |
1345-1358 |
Sentence |
denotes |
29% n.a. n.a. |
| T150 |
1359-1372 |
Sentence |
denotes |
88% n.a. n.a. |
| T151 |
1373-1386 |
Sentence |
denotes |
70% n.a. n.a. |
| T152 |
1387-1390 |
Sentence |
denotes |
83% |
| T153 |
1391-1460 |
Sentence |
denotes |
Chemiluminescent microparticle immunoassay (CMIA) |
| T154 |
1461-1489 |
Sentence |
denotes |
SARS-CoV-2 IgG (Abbott) n.a. |
| T155 |
1490-1503 |
Sentence |
denotes |
29% n.a. n.a. |
| T156 |
1504-1517 |
Sentence |
denotes |
88% n.a. n.a. |
| T157 |
1518-1531 |
Sentence |
denotes |
70% n.a. n.a. |
| T158 |
1532-1536 |
Sentence |
denotes |
100% |
| T159 |
1537-1595 |
Sentence |
denotes |
Chemiluminescence immunoassay (CLIA) |
| T160 |
1596-1640 |
Sentence |
denotes |
Liaison SARS-CoV-2 S1/S2 IgG (DiaSorin) n.a. |
| T161 |
1641-1653 |
Sentence |
denotes |
0% n.a. n.a. |
| T162 |
1654-1667 |
Sentence |
denotes |
81% n.a. n.a. |
| T163 |
1668-1681 |
Sentence |
denotes |
59% n.a. n.a. |
| T164 |
1682-1686 |
Sentence |
denotes |
100% |
| T165 |
1687-1716 |
Sentence |
denotes |
Anti-SARS-CoV-2 (EUROIMMUN)*: |
| T166 |
1717-1757 |
Sentence |
denotes |
IgA instead of IgM; n.a.: not applicable |
